Role of the SHP2 Phosphatase in Myeloid Growth Control and Chronic Myeloid Leukemia
Final rept. 1 Jul 2003-31 Mar 2004
CALIFORNIA UNIV SAN FRANCISCO
Pagination or Media Count:
This final report presents research data from studies performed during the initial 9 month period of a 3 year award from the U.S. Army CML research program. In the fall of 2003, the investigators were notified that an RO1 proposal on the same subject was approved for funding by the National Cancer Institute. After consultation with Army CML program personnel, we voluntarily relinquished this award so that the unused funds could be invested in another research project relevant to improving the care of patients afflicted with CML. The subject of this grant in the SHP-2 protein tyrosine phosphatase, which is mutated in certain chronic myeloid malignancies. We report substantial progress toward accomplishing the goals of this proposal, which include 1 screening JMML, CMML, and CML samples for mutations in the PTPNl 1 gene, which encodes SHP-2 2 to introduce mutant PTPNl 1 alleles into cultured cell lines and primary murine hematopoietic cells to investigate modulation of signal transduction and cell growth in vitro and in vivo and, 3 to generate mice carrying an inducible mutant allele of PTPNl 1 that can be expressed in hematopoietic cells.
- Medicine and Medical Research
- Stress Physiology